Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue
Expenses:
Research and development	254,281
Selling, general and administrative	266,567	196,621
Stock-based compensation	284,793
Impairment of intangible assets	1,966,939
Total expenses	2,772,580	196,621
Loss from operations	(2,772,580)	(196,621)
Other income
Interest income	96	449
Gain on settlement of accounts payable		3,307
Nonoperating Income (Expense), Total	96	3,756
Net loss	$ (2,772,484)	$ (192,865)
Net loss per share - basic and diluted (in dollars per share)	$ (0.04)
Weighted-average number of common shares outstanding - basic and diluted (in shares)	75,356,815	57,032,157